昆药集团股份有限公司 2025年度业绩快报

Group 1 - The company reported a significant decline in revenue and net profit for the year 2025, with expected operating income of 6.577 billion yuan, a decrease of 21.72% year-on-year, and a projected net profit attributable to shareholders of 350 million yuan, down 46% year-on-year [5] - The decline in performance is attributed to multiple factors, including slower-than-expected execution of traditional Chinese medicine procurement, ongoing healthcare cost control policies, and pressure on existing business operations [4] - The company anticipates that the adjustment trend in the pharmaceutical industry will continue into 2026, with internal transformation entering a critical phase [6] Group 2 - The company plans to leverage its strategic partnership with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to enhance its market position in the aging health sector, focusing on channel refinement and brand upgrades [6] - The company aims to improve operational efficiency and cost reduction through various measures, while also enhancing collaboration with its strategic partner to enrich its product matrix and strengthen category linkage [6] - The company expects to gradually return to a healthy and sustainable growth trajectory by enhancing its retail business outside hospitals [6]